An interventional study of Tens Eco Plus in COVID-19, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-22.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 11 under way, 2 of them phase 3. COVID-19 · Assistance Publique - Hôpitaux de Paris.
Among the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, this one is the 47th largest by planned enrollment of the 59 interventional ones that give a count, is one of 7 that started in 2023, is one of 33 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 102nd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →9 of the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–74
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 13 · Phase 3 14
First in 2020; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 150 across the 59 interventional studies, 489 across the 56 observational. Of the 60 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
1 of the studies in COVID-19 by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07882186Assistance Publique - Hôpitaux de ParisAssessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients infected with Covid 19 suffer from frequent pain (headache, migraines, joint pain, muscle pain) in the acute phase which may persist after a stay in intensive care or in an intensive care unit, in the event of post-traumatic stress syndrome, pre-existing comorbidities.
The pain mechanisms observed during the covid epidemic are nociceptive / inflammatory pain, neuropathic pain, and nociplastic pain.
Auricular transcutaneous vagus nerve stimulation (tVNS) is a promising therapeutic strategy that may reduce inflammation and pain level.
Colosat is a prospective non-randomized pilot feasibility study. Colosat is a 8 weeks non randomized trial investigating the painful Covid long.
tVNS will be performed using a transcutaneous lectrical nerve stimulation (TENS) device connected to an auricular electrode stimulating the cutaneous area of the left ear innervated by the auricular ascendant branch of the vagus nerve.
Covid-19 is a disease that presents in several clinical forms (severity and duration). From the end of the first epidemic wave in May 2020, the persistence of symptoms several weeks or months after the first manifestations were described in more than 20% of patients after 5 weeks and more and in more than 10% of patients after 3 months.
In the acute phase, the pains are frequent: headaches / migraines about 13%, joint pain 15%, muscle pain 36%.
In the longer term, patients infected with the coronavirus whose condition necessitated a stay in intensive care have an increased risk of having sequelae (nociceptive or neuropathic) pain. A study carried out 2 years after a stay in an intensive care unit on 164 patients showed that 56% of them suffered from chronic pain. A retrospective study of 80 patients who were hospitalized in the intensive care unit for acute respiratory distress syndrome showed that 38% of them suffered from chronic pain. A meta-analysis of 9 studies and including 1419 patients shows that the incidence or prevalence of pain 3 months after discharge from the intensive care unit ranges from 28 to 77%.
Many viral infections induce neuropathic pain such as Guillain Barré syndrome with an estimated prevalence of 0.5 to 1% and more complex pain syndromes, some of which may suggest nociplastic pain (pain without lesion as in fibromyalgia). There is also a risk of painful chronicization, in particular in the event of post-traumatic stress and / or anxiety-depressive disorders and pre-existing comorbidities (anxiety-depression) There are several pain mechanisms observed during the covid epidemic: nociceptive / inflammatory pain, neuropathic pain, nociplastic pain (without injury).
Pain management is medication with the prescription of analgesics according to the classification of the International Association for the Study of Pain according to the pain-generating mechanism as well as non-drug therapeutic approaches.
Transcutaneous electrical neurostimulation is an analgesic method widely used in Pain Assessment and Treatment Centers in addition to drug analgesics.
The vagus nerve (belonging to the parasympathetic system) is the cranial nerve whose territory is the most extensive having several functions (slowing the heart rate, promoting digestion, improving sleep, etc.). It is a mixed nerve comprising 80% afferent fibers and 20% efferent fibers. It has anti-inflammatory properties both via its afferent fibers capable of activating the corticotropic axis in response to immune stress and, more recently, via its efferent fibers. The release of acetylcholine at the end of its efferent fibers is able to inhibit the release of pro-inflammatory cytokines from splenic macrophages.
This anti-TNF property of the vagus nerve has been used in the treatment of chronic inflammatory bowel diseases but also in rheumatoid arthritis. Any abnormality of the sympathovagal balance can have a pro-inflammatory effect. The reestablishment of this sympathovagal balance is therefore likely to counterbalance a pro-inflammatory process.
In addition, stress also plays a role as it causes vagal inhibition and activation of the sympathetic system thereby promoting the pro-inflammatory reaction. Depending on the environment and the circumstances, stimulation of the vagus nerve can help the body to find the right balance between the sympathetic and parasympathetic systems and therefore a good sympathovagal balance.
Stimulation of the vagus nerve by implantable device, authorized for refractory depression or epilepsy. It has also been considered for several years to treat pain. For pain, a study of 14 patients with fibromyalgia showed a decrease in pain sensitivity corroborated by QST (Quantitative Sensory Testing) before stimulation and at 4, 6, 9 and 12 months after. The use of an implantable device is invasive and is not used in routine practice (surgery).
Functional MRI studies have shown that minimally invasive and inexpensive transcutaneous atrial electrical stimulation (tVNS) (of the left cymba concha) activates the central vagal centers.
However, this stimulation technique (unlike TENS) has been little evaluated for treating pain (3 randomized controlled clinical trials). For induced experimental pain (mechanical pain, pressure pain, thermal pain), atrial tVNS at 25 Hz increased the threshold for mechanical pain and pressure and reduced sensitivity to mechanical pain in 48 healthy subjects (trial controlled cross over). In chronic migraine, a randomized controlled study including 46 patients showed a reduction in the frequency of headaches for 13 to 29% of them depending on the stimulation groups (25Hz versus 1Hz). Another open multicenter study on 50 patients showed a reduction in pain in 64.6% of patients.
tVNS can be performed effectively using a transcutaneous electrical nerve stimulation (TENS) machine. In this case, the TENS machine is coupled to an atrial electrode designed to apply anatomically to contact with the cymba concha in the left ear to avoid parasympathetic cardiovascular effects when stimulated in the right ear.
We want to set up a pilot clinical study to assess the value of this non-drug therapeutic strategy in the overall management of pain from long-term COVIDs. The objective is to have a 1st evaluation of the efficacy, tolerance and feasibility of transcutaneous atrial vagus nerve stimulation (tVNS) in the various pain mechanisms (nociceptive, neuropathic and nociplastic) observed during the Covid-19. Depending on the results, a randomized controlled trial may then be set up. ?
Colosat is a 8 weeks non randomized trial investigating the painful Covid long. tVNS will be performed using a transcutaneous lectrical nerve stimulation (TENS) device connected to an auricular electrode stimulating the cutaneous area of the left ear innervated by the auricular ascendant branch of the vagus nerve.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects aged 18 to 80 with prolonged post-Covid-19 pain defined by 3 criteria according to the Haute Autorité de Santé :
Initial and prolonged symptoms not explained by another diagnosis with no known link to Covid-19
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30min/day of stimulation at 25Hz frequency, 100 microsc pulse with intensity escalation up to 25 mA max
Pain
Difference D0-M2 of self-reported pain post Covid-19 (COVID Long) measured in a 100 mm on a Visual Analog Scale (VAS). The patient assesses the pain of the last eight days before the visit.
Time frame: 2 months
Analgesics
consumption of analgesics during visits on D0 and M2 (modification of doses)
Time frame: 2 months
PGIC
Patient global impression of change at M2
Time frame: 2 months
Quality of life
improvement of the quality of life between Do and M2
Time frame: 1 and 2 months
Side effects
report of side effects during the study period
Time frame: 1 and 2 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2023 (actual). Primary completion is estimated for Mar 2025, 26 months after the start.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 26 months is above that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →